Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Clemons, MD
Princess Margaret Hospital, Toronto
Principal Investigator - Mika Sovak, MD PhD
AstraZeneca
Study Director - Rebecca Dent, MD
Sunnybrook Health Sciences Centre, Toronto
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Auchenflower, Australia
- Research Site
Parkville, Australia
- Research Site
Perth, Australia
- Research Site
Vienna, Austria
- Research Site
Leuven, Belgium
- Research Site
Toronto, Ontario, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Sept 2008
- Primary completion
- 9 Nov 2009
- Completion
- 19 Feb 2018
- Last update posted
- 6 Mar 2018
- Registered enrollment
- 19
- Registry id
- NCT00707707
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.